
Delcath Systems, Inc. CHEMOSAT Added to ESMO–EURACAN Guidelines for Uveal Melanoma
Delcath Systems Secures Key Guideline Recognition for CHEMOSAT in Uveal Melanoma Treatment Delcath Systems, Inc., an interventional oncology company specializing in liver-directed cancer therapies, has announced a significant milestone for its proprietary CHEMOSAT® Hepatic Delivery System for Melphalan. The therapy,…












